Enhances cells proliferation by activating mTOR/MAPK/ERK pathways in polycystic kidney disease (Yamamoto et al., 2017)Reduces GFR and renal plasma flow, increase plasma free FAs and kidney smooth muscle actin (α-SMA), collagen level in 5/6 nephrectomy rats (Pillai et al., 2019)Reduces kidney glomeruli number in a doxorubicin toxicity model (Duarte et al., 2023)Downregulated serum creatinine at day 28 in UUO-induced AKI (Jouret et al., 2016). This evidence concerns the gene MTOR and polycystic kidney disease.